Somatostatin Analogs Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

The Somatostatin Analogs Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Somatostatin Analogs Market:

https://www.thebusinessresearchcompany.com/report/somatostatin-analogs-global-market-report

According to The Business Research Company’s Somatostatin Analogs Global Market Report 2024, The somatostatin analogs market size has grown strongly in recent years. It will grow from $6.23 billion in 2023 to $6.68 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The  growth in the historic period can be attributed to increased net incidence, advancements in oncology research, clinical efficacy in symptom management, expansion of indications, patient preference for long-acting formulations..

The somatostatin analogs market size is expected to see strong growth in the next few years. It will grow to $8.67 billion in 2028 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to continued rise in net incidence, research focus on rare diseases, development of combination therapies, advancements in personalized medicine, global health initiatives in cancer care.. Major trends in the forecast period include global aging population, healthcare infrastructure development in emerging markets, strategic collaborations and partnerships, pricing pressures and reimbursement challenges, technological integration in healthcare..

The rise in the incidence of neuroendocrine tumors is expected to propel the growth of the somatostatin analogs market going forward. Neuroendocrine tumors refer to malignancies that start in specialized neuroendocrine cells. Analogs of somatostatin prevent the body from producing too many hormones. They decrease a neuroendocrine tumor’s growth and reduce carcinoid disease symptoms. For instance, according to Cancer Australia, an Australia-based national government agency, in 2022, around 5,437 new cases of neuroendocrine tumors were diagnosed in Australia, and it was estimated that a person has a 1 in 55 risks of being diagnosed with neuroendocrine tumors by the age of 85. Therefore, the rise in the incidence of neuroendocrine tumors is driving the growth of the somatostatin analogs market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=10840&type=smp

The somatostatin analogs market covered in this report is segmented –

1) By Type: Octreotide, Lanreotide, Pasireotide

2) By Treatment: Acromegaly, Cushing’s Syndrome, Neuroendocrine Tumors, Carcinoid Syndrome, Other Treatments

3) By End User: Hospital, Pharmaceutical Companies

Innovation of novel drug therapies is a key trend gaining popularity in the somatostatin analog market. Major companies operating in the somatostatin analogs market are developing innovative drug therapies to strengthen their position in the market. For instance, in December 2021, Xeris Biopharma Holdings, Inc, a US-based biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, announced the U.S. Food and Drug Administration (FDA) approval of Recorlev (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. With this approval, Xeris’ experienced endocrinology-focused commercial organization can begin rapidly working to help address the needs of Cushing’s syndrome patients in the U.S. who are treated with prescription therapy.

The somatostatin analogs market report table of contents includes:

 

  1. Executive Summary
  2. Somatostatin Analogs Market Characteristics
  3. Somatostatin Analogs Market Trends And Strategies
  4. Somatostatin Analogs Market – Macro Economic Scenario
  5. Global Somatostatin Analogs Market Size and Growth

 

.

.

.

  1. Global Somatostatin Analogs Market Competitive Benchmarking
  2. Global Somatostatin Analogs Market Competitive Dashboard
  3. Key Mergers And Acquisitions In The Somatostatin Analogs Market
  4. Somatostatin Analogs Market Future Outlook and Potential Analysis
  5. Appendix

Top Major Players:

  • Novartis International AG
  • Pfizer Inc
  • Midatech Pharma PLC
  • Crinetics Pharmaceuticals Inc
  • Peptron Inc

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: [email protected]

 

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company  

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ  

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/  

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model